Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Angiography request, University Hospital Cologne

- 16/04/2017 - 1 Formulaire, 2 Groupes Item, 25 Eléments de données, 1 Langue

Groupes Item: RIS Request, Angiography Request

Hospital Routine Documentation Subform at the University Hospital Cologne. Original Form name: Angiograph_Anford

Eligibility Recurrent Prostate Cancer NCT00775866

- 10/06/2017 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00775866

Palliative and Hospice Care Advanced Diagnostic Procedures

- 11/05/2016 - 1 Formulaire, 9 Groupes Item, 59 Eléments de données, 2 Langues

Groupes Item: Microbiological tests, Therapeutic consequences from laboratory result, Ultrasound, X-ray, CT / MRI, radio imaging, Issues during diagnostic imaging, Therapeutic consequences from diagnostic imaging, Form Information

https://www.hope-clara.de/ The HOPE Hospice and Palliative Care Recording standard documentation is used for documentation of palliative care and as an instrument for quality assurance in pallatiave wards, hospices and oncological wards as well as in ambulatory services and palliative teams.

DELCODE: DZNE – Longitudinal Cognitive Impairment and Dementia Study - Cumulative documentation - Procedures (Kumulative Dokumentation - Prozeduren)

- 23/03/2020 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue

Groupes Item: Administrative Data, Procedures

DELCODE is conducted by DZNE, the German Center for Neurodegenerative Diseases within the Helmholtz Association. The following information was taken from https://www.dzne.de/en/research/studies/clinical-studies/delcode/. Background and aims: One of the important aims of research into Alzheimer's is to find ways of detecting the disease early – if at all possible, as soon as the first minor symptoms appear, or even before any symptoms at all have appeared. Such detection capabilities are the necessary basis for development of therapies that can be applied at such early stages in the disease. Recent research indicates that such therapies could be more effective than therapies initiated during the disease's later stages. Over a period of several years, the DELCODE study is studying persons in early stages of the disease, along with various risk groups. The research is aimed at the development of procedures for characterizing early stages of the disease, at improving prediction of the course of the disease and at identifying new markers for early diagnosis of Alzheimer's-related dementia. Overview: DELCODE is set up to run for an initial period of three years, and to include a total of 1,000 study participants, who will be examined on a yearly basis. The group of participants will include persons with no complaints (healthy control subjects), patients with slight memory impairment or mild dementia and first-degree relatives of patients with diagnosed Alzheimer's disease. The minimum age for participants is 60. Course of the study: The examinations in the framework of the study will include a comprehensive interview carried out by a study investigator, a detailed neuropsychological examination (testing of memory functions and other areas of cognitive performance), a blood test and a cranial MRI scan. Optionally, subject to the study participant's consent in each case, a lumbar puncture (collection of cerebrospinal fluid) will be carried out." For more information (e.g. principle investigator and study coordination), please visit the above link or https://www.dzne.de. This document contains the cumulative documentation - procedures. Prior procedures should be filled in at baseline. Procedures that are performed during the study period should be added in the course of the study.

visit 1 (medical evaluation) salmeterol/fluticasone propionate combination compared to salmeterol on COPD 100470

- 08/08/2017 - 1 Formulaire, 17 Groupes Item, 47 Eléments de données, 1 Langue

Groupes Item: administrative data, demography, medical condition, tobacco use, COPD, oropharyngeal candidasis examination, Chest x-ray, modified medical research council dyspnoea scale, 12-lead ECG, pulmonary function testing, pulmonary funtion testing: FEV1, pulmonary function testing: FVC, pulmonary function testing: FEV1 /FVC ratio, fat free mass, laboratory blood, St. George's respiratory questionnaire, baseline dyspnoea index

Study ID: 100470 Clinical Study ID: SCO100470 Study Title: A multicentre, randomised, double-blind, parallel group, 24 week study to compare the effect of salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via DISKUS®/ACCUHALER® inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor:GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Serevent Study Indication: Pulmonary Disease, Chronic Obstructive